 | Up a level |
Felip, Enriqueta, Ardizzoni, Andrea, Ciuleanu, Tudor, Cobo, Manuel, Laktionov, Konstantin, Szilasi, Maria, Califano, Raffaele, Carcereny, Enric, Griffiths, Richard, Paz-Ares, Luis, Duchnowska, Renata, Alonso Garcia, Miriam, Isla, Dolores, Jassem, Jacek 
ORCID: 0000-0002-8875-6747, Appel, Wiebke, Milanowski, Janusz, Van Meerbeeck, Jan P., Wolf, Juergen, Li, Ang, Acevedo, Angelic and Popat, Sanjay ORCID: 0000-0003-2087-4963
(2020).
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Eur. J. Cancer, 127.
S. 160 - 173.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1879-0852
Horn, Leora, Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Paik, Paul, Li, Ang, Xu, Dong, Neely, Jaclyn, Qi, Zhenhao, Harbison, Christopher, Lynch, Mark and Ramalingam, Suresh S. (2015). Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. J. Thorac. Oncol., 10 (9). S. S175 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380